Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study.

doi:10.1128/spectrum.00897-24

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study.

Microbiology spectrum - 7 Jan 2025

De Marco Laura, Bisanzi Simonetta, Ronco Guglielmo, Mancuso Pamela, Carozzi Francesca, Allia Elena, Rizzolo Raffaella, Gustinucci Daniela, Frayle Helena, Viti Jessica, Iossa Anna, Cesarini Elena, Bulletti Simonetta, Passamonti Basilio, Gori Silvia, Toniolo Laura, Venturelli Francesco, Del Mistro Annarosa, Giorgi Rossi Paolo, Benevolo Maria

Abstract excerpt

The use of clinically validated human papillomavirus (HPV) assays is recommended in cervical cancer screening, and extended genotyping is getting attention as a triage biomarker because of the different oncogenic risk of the high-risk HPV genotypes. We compared the results of the Becton & Dickinson (BD) Onclarity HPV assay, on the residual baseline cervico-vaginal specimens of the NTCC2 trial, to those of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Early Detection of Cancer

Share to Genotyping Techniques

Share to Mass Screening

Share to Papillomaviridae

Share to Papillomavirus Infections

Share to Uterine Cervical Neoplasms

Source

Open in PubMed

Identifiers

PMID: 39576120
DOI: 10.1128/spectrum.00897-24

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study.PMID 39576120Read ↗

Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study.Semantic proximity Read ↗

Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.Semantic proximity Read ↗

Impact of differentiating between persistent and new infections on colposcopy referral in HPV-positive triage-negative women: results from the NTCC2 studySemantic proximity Read ↗

Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.Semantic proximity Read ↗

Genotyping and Cytology Triage of High-Risk HPV DNA Positive Women for Detection of Cervical High-Grade Lesions.Semantic proximity Read ↗

Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.Semantic proximity Read ↗

Extended HPV genotyping and dual stain for the triage of primary HPV screen-positive cases: Practical guidance for the cytopathology laboratory.Semantic proximity Read ↗

Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.Semantic proximity Read ↗

Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results.Semantic proximity Read ↗

Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting.Semantic proximity Read ↗

Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytologySemantic proximity Read ↗

Molecular tests potentially improving HPV screening and genotyping for cervical cancer preventionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.